Back to Search
Start Over
Recombinant human tyrosyl-tRNA synthetase, a novel thrombopoietic agent.
- Source :
-
European Journal of Pharmacology . Sep2014, Vol. 738, p293-300. 8p. - Publication Year :
- 2014
-
Abstract
- Chemo- and radiotherapy induced thrombocytopenia present significant limitations for tumor therapy. In this study, we examined the therapeutic effect of recombinant human tyrosyl-tRNA synthetase (rhTyrRS) against development of thrombocytopenia in cyclophosphamide (CTX) treated mice. Our data indicate that intraperitoneal administration of at least 10 μg/day rhTyrRS for 7 days significantly prevents the decrease in platelets 8 days after CTX injection. The data further demonstrate that rhTyrRS promotes migration and aggregation of megakaryocytes to the bone marrow niche. Real-time PCR and flow cytometry reveal that VCAM-1 is particularly important for the adhesion. Together, these data suggest that rhTyrRS might be a useful therapeutic agent for chemotherapy-induced thrombocytopenia. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 00142999
- Volume :
- 738
- Database :
- Academic Search Index
- Journal :
- European Journal of Pharmacology
- Publication Type :
- Academic Journal
- Accession number :
- 97186661
- Full Text :
- https://doi.org/10.1016/j.ejphar.2014.05.054